NCT07217587 2026-04-13
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
15 trialsNCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06744920 2026-04-06
RELIEVE
Novartis
Phase 3 Recruiting
NCT06607627 2026-04-01
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06517758 2026-03-30
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06799247 2026-03-24
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
Phase 3 Recruiting
NCT06463587 2026-03-19
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT06456580 2026-03-10
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT07039916 2026-03-06
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT04951622 2026-03-03
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07215949 2026-02-23
Zilucoplan for Severe gMG Exacerbations
Ohio State University
Phase 3 Recruiting
NCT06342544 2026-01-21
IMCOMG
Fondation Ophtalmologique Adolphe de Rothschild
Phase 3 Recruiting
NCT05868837 2025-08-01
REFINE
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Recruiting
NCT06765161 2025-07-29
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Phase 3 Recruiting
NCT06587867 2024-09-19
Seronegative Myasthenia Gravis - Efgartigimod IV
University Health Network, Toronto
Phase 3 Recruiting